In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.

Xbrane has resubmitted its filing for a ranibizumab biosimilar version of Lucentis to the FDA, suggesting that it could receive approval in the first half of next year.

April brings news of further biosimilar competition to Lucentis in major European markets.

Stada has celebrated “growing faster than the markets in which it operates” after delivering a 2022 performance that saw the firm’s earnings lifted in particular by increases in its consumer healthcare and specialty segments.